- In a deal revealed Nov. 6th, Champions Oncology has partnered with Insilico Medicine to compare biomarker profiles between patient tumor and mouse grafted-tumor.
- Champions TumorGraft Technology will allow oncolytic pharmaceuticals to be tested in patient-specific tumors at a fraction of current healthcare costs.
- With a previous association with Teva Pharmaceuticals, this partnership may signal a further push into personalized medicine drug discovery and pharmaceutical re-purposing for CSBR.
We currently have no Breaking News on this stock.
CSBR vs. ETF Alternatives
Champions Oncology, Inc. (the "Company"), is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the... More
Other News & PR